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Abstract
Human papillomavirus (HPV)–related head and neck squamous cell carcinoma (HNSCC) incidence is increasing at a
near epidemic rate. We investigated whether the mammalian (or mechanistic) target of rapamycin (mTOR) inhibitor,
rapamycin, can be used as a concurrent agent to standard-of-care cisplatin/radiation therapy (CRT) to attenuate tumor
lactate production, thus enhancing CRT-induced immune-mediated clearance of this antigenic tumor type. A C57Bl/
6-derived mouse oropharyngeal epithelial cell line retrovirally transduced with HPV type 16 E6/E7 and human squa-
mous cell carcinoma cell lines were evaluated for their response to rapamycin in vitro with proliferation assays,
Western blots, and lactate assays. Clonogenic assays and a preclinical mouse model were used to assess rapamycin
as a concurrent agent to CRT. The potential of rapamycin to enhance immune response through lactate attenuation
was assessed using quantitative tumor lactate bioluminescence and assessment of cell-mediated immunity using
E6/E7-vaccinated mouse splenocytes. Rapamycin alone inhibited mTOR signaling of all cancer cell lines tested
in vitro and in vivo. Furthermore, rapamycin administered alone significantly prolonged survival in vivo but did not
result in any long-term cures. Given concurrently, CRT/rapamycin significantly enhanced direct cell killing in clonogenic
assays and prolonged survival in immunocompromised mice. However, in immunocompetent mice, concurrent
CRT/rapamycin increased long-term cures by 21%. Preliminary findings suggest that improved survival involves
increased cell killing and enhanced immune-mediated clearance in part due to decreased lactate production. The
results may provide rationale for the clinical evaluation of mTOR inhibitors concurrent with standard-of-care CRT for
treatment of HPV-positive HNSCC.
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Introduction
Three to five percent of all cancers reported in the United States are
head and neck squamous cell carcinomas (HNSCCs), with more than
40,000 cases reported annually [1]. Survival rates for this type of can-
cer are poor. Only about 50% of patients will survive over the 5-year
period following diagnosis. Though incidence of head and neck cancer
is on a general decline, correlating with decreasing smoking prevalence
[2], human papillomavirus (HPV)–related HNSCC is increasing at a
near epidemic rate with incidence nearly tripling over the last 30 years
[3,4]. Of the more than 40,000 reported annual cases of HNSCC in
the United States, at least 25% are HPV type 16 (HPV-16) positive
and roughly 40% result in death [5–7]. More specifically, an even
greater proportion (60–80%) of oropharyngeal HNSCC is HPV-16
positive (HPV+). These tumors present with more advanced stage dis-
ease compared to their histologically identical HPV-negative (HPV−)
counterparts [5,6,8]. Though more advanced, HPV+ tumors para-
doxically leave patients with an improved prognosis with standard-of-
care combined modality treatment, which typically includes surgery,
cisplatin, and radiation. The improved prognosis is likely imparted
by the antigenic nature of this tumor type [2,9], though it has also been
attributed to maintenance of functional unmutated p53 [5]. While
HPV+ HNSCCs have an improved survival compared to HPV−
counterparts, the increasing incidence makes understanding this disease
a priority. Although successful in at least 80% of patients, treatments
also leave patients with significant morbidity associated with eating
and speaking. Together, increasing disease burden and significant
treatment-related morbidity necessitate the need to develop better
therapies or dose-reducing adjuvants.
One of the key cancer characteristics that contribute to the poor
prognosis of HNSCC is altered cellular metabolism. Unlike normal
cells, which generate energy through oxidative phosphorylation, cancer
cells use high rates of glycolysis to generate cellular energy and pro-
duce biosynthetic intermediates. This allows them to live in low- and
fluctuating oxygen environments [10]. Normal cells use oxidative phos-
phorylation through the tricarboxylic acid cycle and electron transport
chain, fermenting only under hypoxic conditions when the greater en-
ergy producing tricarboxylic acid–electron transport chain pathway
cannot be used. Cancer cells, however, alter key metabolic enzymes that
allow them to thrive in low-oxygen environments. This phenomenon
is known as the Warburg effect, or aerobic glycolysis, in which cancer
cells use glycolysis and fermentation of pyruvate into lactate as a pri-
mary energy pathway even in the presence of sufficient oxygen [11].
The most common subset of hypermetabolic HNSCC is that caused
by HPV [12]. Expression of the HPV E6 oncoprotein causes p53
degradation, and this is required for malignant transformation by the
virus. Although not fully understood, HPV oncogenes play a role
in conferring the metabolic phenotype of related HNSCC. Recent
evidence has suggested that the E6 oncoprotein also alters cellular
metabolism [13]. The E6 oncoprotein has been shown to promote
a highly metabolic phenotype through increases in mammalian (or
mechanistic) target of rapamycin (mTOR) activity [14]. mTOR
activity is upregulated in head and neck cancers and plays a critical
role in controlling factors that impact local recurrence and survival
in HNSCC, including metabolism [15–17]. Specifically, mTOR
increases expression of hypoxia-inducible factor 1α (HIF1α) and sub-
sequently pyruvate kinase M2, lactate dehydrogenase (LDH), pyruvate
dehydrogenase kinase 1, and GLUT1, among other proteins regulated
by the hypoxia response element [18,19]. Through these pathways, E6
activation of mTOR plays a role in altering cellular metabolic function.
The mTOR inhibitor, rapamycin (sirolimus), is commonly used in
combination with glucocorticoids and cyclosporine to prevent organ re-
jection. Even at these synergistic, immunosuppressive doses, it is well
tolerated and has minimal toxicity [15,16], making it an attractive ad-
juvant along with already being approved for use in human patients.
Used alone, rapamycin does not cause significant immune suppression
but instead has been shown to prevent progression, slow growth, and
impede angiogenesis and lymphangiogenesis in various tumor models,
including head and neck [20–24]. The reliance of head and neck cancers
on the mTOR signaling pathway has led to increased interest in using
rapamycin as a head and neck cancer treatment specifically [15,16].
We have recently shown that an immune response is required
for long-term cures of HPV+ HNSCC following standard cisplatin/
radiation therapy (CRT) [9] and that this immune-mediated clearance
is CD8+ dependent [25]. While activated mTOR signaling promotes
lactate production as a byproduct of upregulated metabolism, lactate
in the tumor microenvironment has been shown to inhibit immune
cell functions [26–28], including those specific for CD8+ cells [29].
We thus hypothesized that appropriately inhibiting tumor metabolism
through inhibition of mTOR may improve survival by at least two
mechanisms: 1) enhanced direct cell toxicity due to blocking of key
survival signals and 2) attenuation of tumor lactate production that
could enhance immune-mediated tumor clearance. To investigate
this hypothesis, we examined how inhibition of mTOR signaling by
rapamycin alone affects growth and how it synergizes with CRT to po-
tentially enhance therapeutic efficacy. Though classified as an immuno-
suppressant, indeed rapamycin has also been shown to have particular
immune-enhancing capabilities ([30,31] and references therein). Here,
we show that mTOR inhibition by rapamycin, along with the con-
sequent reduction of lactate levels, may be a relatively safe, nontoxic
way to both enhance direct CRT-induced cytotoxicity and the tumor
clearing immune response to HPV+ HNSCC.
Materials and Methods
Cell Lines, Culture Conditions, and Authentication
Mouse oropharyngeal epithelial cells (MOEs) were previously inter-
nally derived from C57Bl/6 mouse oropharyngeal epithelium retro-
virally transduced with the indicated vectors and oncogenes [7].
MOEs are routinely internally screened for the presence of cytokeratin
and HPV-16 mRNA as means of authentication, and our model HPV+
HNSCC line harboring the E6, E7, and mutated H-RasV12 oncogenes
(E6/E7/Ras MOEs) [32] is routinely grafted into syngeneic mice for
animal studies. Human squamous cell carcinoma cell (SCC) lines 1,
47, and 84 were a generous gift from Dr Douglas Trask (University
of Iowa, Iowa City, IA). These human cell lines were originally gener-
ated at the University of Michigan (UM-SCCs; Ann Arbor, MI) by the
Head and Neck SPORE Translational Research Group. This group has
completed genotyping of 73 published UM-SCC cell lines [33]. Results
from continued efforts to genotype remaining and newly generated cell
lines are posted on the UM Head and Neck SPORE Tissue Core web
site (http://www2.med.umich.edu/cancer/hnspore/cores-tissue.cfm).
The UM-SCC cell lines used in this work were authenticated by
Genetica DNA Laboratories (Cincinnati, OH) through DNA profil-
ing and are also routinely internally screened for HPV-16 mRNA.
The SCC90 cell line was a gift during the period of this work from
Dr Randall Kimple (University of Wisconsin, Madison, WI) who
received it directly from the University of Pittsburgh (UP-SCC90).
MOEs and SCCs were maintained in Dulbecco’s modified Eagle’s
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medium (Hyclone, Logan, UT) supplemented with 10% FBS (Atlanta
Biologicals, Lawrenceville, GA), 100 U/ml penicillin (Hyclone),
100 μg/ml streptomycin (Hyclone), and 250 ng/ml amphotericin B
(CellGro, Manassas, VA). Primary human tonsil epithelial cells (HTEs)
were internally cultured from normal human tonsil epithelium, and
experiments were performed within three passages. Primary HTEs
were cultured in keratinocyte serum-free media supplemented with
0.025 mg/ml bovine pituitary extract (Gibco, Grand Island, NY) and
1.6 × 10−4 μg/ml epidermal growth factor (Gibco). All cells were cultured
at 37°C in a 5% CO2 humidified atmosphere.
Cell Proliferation and Lactate Assays
Cell lines were plated in triplicate and allowed to establish for
24 hours before treating with the indicated concentrations of rapamycin
(LC Laboratories, Woburn, MA) dissolved in DMSO in culture media.
After 72 hours, all cells were isolated, resuspended, and stained 1:1 with
0.4% trypan blue (Sigma-Aldrich, St Louis, MO). Live and dead cell
numbers were counted through a hemacytometer with live cell number
presented as percent of control live cell number. Lactate levels in the
culture media were determined using colorimetric enzymatic assays.
Cells were plated in triplicate and allowed to grow to 100% confluence
before treating with the indicated concentrations of rapamycin for
4 hours. Culture media was then subject to the standard protocol of a
commercially available lactate assay kit (Eton Bioscience, San Diego,
CA). Absorbance (A490) was read on a SpectraMax Plus 384 plate
reader, and a standard curve was generated for back-calculation of lac-
tate concentration.
Clonogenic Assays
Cells were plated in triplicate at 2500 E6/E7/RasMOEs per 100-mm
dish for each of the indicated rapamycin concentrations. Cells were
allowed to establish for 24 hours before beginning a 1-day pretreatment
of rapamycin, mimicking our in vivo treatment regimen. Media con-
taining both the indicated concentration of rapamycin and 0.5 μg/ml
cisplatin (Calbiochem, Darmstadt, Germany) dissolved in normal saline
were then replaced. After a 1-hour incubation, all cells were irradiated
(4 Gy) and returned to the incubator. A week from the initiation of treat-
ment, cells were fixed in 70% ethanol and stained with 0.5% crystal
violet (Fisher, Waltham, MA) in 10% ethanol. Average size and number
of colonies, defined as a minimum of 50 cells, were quantified using
an AlphaImager System and corresponding image analysis software
(AlphaInnotech, Santa Clara, CA).
Western Blot Analysis of the mTOR Pathway
Cells were harvested in a sodium dodecyl sulfate (SDS)–containing
buffer [2.5 mM Tris-HCl (pH 6.8), 2.5% SDS, 100 mM DTT, 10%
glycerol, and 0.025% pyronine Y] at 24 hours, sonicated, and heated
before running. Equal amounts of protein were separated by SDS–
polyacrylamide gel electrophoresis and transferred to polyvinylidene
difluoride (PVDF) membrane through semidry transfer apparatus.
Antibodies for detection of proteins of interest were diluted in blocking
buffer, 5% BSA or nonfat dry milk in tris-buffered saline with tween
(TBST), as recommended for individual antibodies: phosphorylated
p70 S6 kinase (P-S6K; Thr389, #9206; Cell Signaling Technology,
Danvers, MA), p70 S6K (#9202; Cell Signaling Technology), 4E-BP1
(R-113, sc-6936; Santa Cruz Biotechnology, Santa Cruz, CA). Signal
was detected usingHRP-conjugated secondary antibodies andAmersham
ECL prime detection reagent (GEHealthcare, Little Chalfont, United
Kingdom). Exposures were captured using a charged-coupled device
(CCD) camera imaging system (UVP, Upland, CA).
Animal Studies
Our in vivo model of HPV+ HNSCC was used as described previ-
ously [9]. All experiments were performed in accordance with insti-
tutional and national guidelines and regulations with the protocol
approved by the Animal Care and Use Committee at Sanford Research.
Briefly, 1 × 106 E6/E7/Ras MOEs were injected into the right subcu-
taneous flank of syngeneic male C57Bl/6 mice (immune competent) or
B6.129S7-Rag1tm1Mom/J (RAG-1 or Rag) mice (immunocompromised,
lacking mature B and T cells). Tumors were allowed to establish for 1 to
2 weeks before treatment administration. Mice were administered rapa-
mycin intraperitoneally (i.p.) in a 5.2% Tween 80 (Sigma-Aldrich),
5.2% PEG-400 (Hampton Research, Aliso Viejo, CA) phosphate-
buffered saline vehicle at 0 to 5.0 mg/kg as previously described [22].
Rapamycin or vehicle was administered daily to end point or for
21 days when concurrent with 3 weeks of once weekly i.p. cisplatin
(0.132mg/mouse) dissolved in normal saline and once weekly radiation
(8 Gy; 24 Gy total) to the affected flank. Tumor dimensions were mea-
sured weekly to monitor growth. Mice with tumors obtaining a volume
of 3000 mm3 or becoming substantially emaciated were euthanized.
When all mice reached end point or a maximum of 100 days passed,
Kaplan-Meier survival analysis was performed on the basis of exponen-
tial regressions of individual tumor volume curves, standardizing sur-
vival to the predefined 3000-mm3 tumor volume end point.
Tumor Immunohistochemistry and Lactate Bioluminescence
Anti–phospho-S6 (Ser235/236, #2211S; Cell Signaling Technology)
was used for immunohistochemical analysis of paraffin-embedded
tumors harvested from daily rapamycin- or vehicle-treated mice at end
point as previously described [22]. Stained slides were scanned with
an Aperio CS Scanscope. Quantitative tumor lactate bioluminescence
was performed as recently described by Broggini-Tenzer et al. [34].
Twenty-micrometer sections of tumors as described above, flash-frozen
in freezing media optimal cutting temperature (OCT), were heat inacti-
vated (100°C) on standard microscope slides. Fifty microliters of lactate-
dependent luciferase-containing buffer was added to each tumor section
followed by immediate imaging on a Carestream In Vivo Xtreme Small
Animal Imaging System. Average intensities of each section were deter-
mined using the provided Carestream software.
Cell-mediated Immunity Assay
Carboxyfluorescein succinimidyl ester (CFSE; Invitrogen, Grand
Island, NY)–stained E6/E7/Ras cells were irradiated (30 Gy) and
co-cultured 1:10 (target/effector) for 24 hours with isolated mixed
lymphocytes from the spleens of mice intranasally vaccinated with
a previously developed adenoviral recombinant vaccine expressing
HPV-16 E6 and E7 (adenovirus 5 E6/E7, or Ad5 E6/E7) [6] at the in-
dicated concentrations of lactic acid (Sigma-Aldrich) in media (RPMI,
supplemented as Dulbecco’s modified Eagle’s medium above; Hyclone)
followed by dead cell staining (TO-PRO-3; Invitrogen) and flow cytom-
etry. Using an Accuri C6 Flow Cytometer and CFlow Plus software
(BD-Accuri, Ann Arbor, MI), CFSE-positive cells were gated using
the FL2 channel and mean TO-PRO-3 signal averaged for each dosage
group using the FL4 channel. Isolated lymphocytes, as described above,
were also cultured alone for detection of levels of intracellular perforin.
The cells were cultured at the indicated concentrations of lactic acid in
media at a cell density of 2.5 × 106 cells/ml for 24 hours, followed by
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pelleting and lysing in an SDS-containing buffer for Western blot, as
described above. Perforin antibody (#3693; Cell Signaling Technology)
was diluted in 5% BSA in TBST as recommended for detection by
Western blot.
Statistical Analysis
Error bars displayed are SDs from the mean of at least three repli-
cates. Comparison of two groups was done using two-tailed pairwise
Student’s t tests. Regarding Kaplan-Meier survival analysis, log-rank
significance tests were performed with P values generated using the
pairwise multiple comparisons Holm-Sidak method. P values less than
or equal to .05 were considered to have significance.
Results
Rapamycin Inhibits HPV+ HNSCC Cell Proliferation with
Associated Decreases in mTOR Signaling
Activation of mTOR and its modulation by multiple cellular pathways
is a common feature of HNSCC. To assess the potential of rapamycin
to inhibit this frequently altered pathway in HNSCC, we examined the
effects in vitro on cell growth and signaling in primary HTEs (1°), two
HPV− SCC cell lines (SCC1 and SCC84), and two HPV+ SCC cell
lines (SCC47 and SCC90). All of the cells tested were treated with 0
to 100 nM rapamycin for 72 hours and were inhibited in growth in a
dose-dependent manner (all lines at 10–100 nM rapamycin, P ≤ .047
to untreated control), with 1°HTEs appearing the least sensitive to higher
doses (Figure 1A), though all cell lines were inhibited in mTOR signal-
ing. This was evidenced by decreases in phosphorylated downstream
targets p70 S6K (P-S6K) and eukaryotic initiation factor 4E binding
protein 1 (4EBP1) seen by Western blot (Figures 1B and W1). These
findings reflect the increased mTOR dependence of HNSCC [15,35]
over normal epithelium, the latter as recently shown for normal oral
keratinocytes [36], and suggest that rapamycin has the potential to ex-
ploit this mTOR dependence, including the presumably high mTOR
dependence imposed by the E6 oncoprotein in HPV+ HNSCC [14].
We extended these findings to our immortalized MOEs harboring
either empty vector (LXSN) or HPV-16 E6 and E7 (E6/E7). These
cells were also treated with rapamycin at the indicated doses after
which cell viability was determined (Figure 1C ). Both cell lines were
inhibited in mTOR signaling (Figures 1D and W1) and responsive
to rapamycin treatment in a dose-dependent manner. A caveat is that
the empty vector control cell line is an immortalized line and may have
greater mTOR dependence than primary epithelial cells and thus shows
greater sensitivity to rapamycin. To this end, these findings together
with those in the human cells support the potential efficacy of rapamycin
in HPV+ HNSCC and warranted further studies.
Figure 1. Inhibition of cell proliferation of human andmouseHNSCC cell lines by rapamycin is associatedwith decreases inmTOR signaling.
(A) Cell proliferation assay. Primary HTEs are compared to four tonsillar SCC lines, two HPV− (SCC1 and SCC84) and two HPV+ (SCC47 and
SCC90), after 72 hours of rapamycin treatment at the indicated concentrations. (B) Western blot analysis of downstream targets of mTOR.
Whole-cell lysates of the cell lines described in A after 24 hours of 10 nM rapamycin treatment were analyzed for protein levels downstream
of mTOR. (C) Mouse correlate to A. A retrovirally transduced and immortalized HPV+ mouse oropharyngeal epithelial (MOE) cell line
possessing the E6 and E7 oncogenes (E6/E7) is compared to an empty vector containing control line (LXSN). (D) Corresponding mouse
correlate Western blots of downstream targets of mTOR. All cell lines treated with rapamycin showed a dose-dependent decrease in cell
proliferation (all lines at 10–100 nM rapamycin, P≤ .047 to control). Regarding Western blots, with rapamycin treatment, total S6K migrates
slightly faster, indicating dephosphorylation. Phosphorylation of S6K (P-S6K) is nearly completely inhibited, and 4EBP1 shows decreases in
the slower migrating, hyperphosphorylated bands and increases in the faster migrating, hypophosphorylated bands. Blots have been
cropped for presentation and those with dark backgrounds have been enhanced in contrast and brightness in entirety using Microsoft
PowerPoint before cropping. Full-length blots can be seen in Figure W1.
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Rapamycin Enhances Direct CRT-Induced Cytotoxicity
Many HPV+ cancers are currently treated with concurrent cis-
platin and radiation [9,37]. Chemotherapy and radiation are known
to activate survival signals through the phosphatidylinositol 3-kinase
(PI3K)/Akt/mTOR pathways [38]. Evidence exists for separate radio-
sensitizing and chemotherapeutic enhancing effects of mTOR inhibi-
tion by rapamycin [16,38], and chemotherapy itself is radiosensitizing
[15]. However, rapamycin has not been studied extensively in combina-
tion with both cisplatin and radiation for HPV+ HNSCC. To assess the
ability of rapamycin to enhance the direct cell toxicity of CRT, we used
clonogenic assays. Cells were plated 24 hours before a 1-day pretreat-
ment with rapamycin before adding cisplatin and irradiating. In such
a manner, we mimicked the treatment regimen used in our animal
studies. Dose escalation of rapamycin with stable doses of concurrent
cisplatin and radiation resulted in a dose-dependent decrease in colonies
formed (1 nM, P < .03; 10 nM, P < .01) and at significantly smaller
sizes (P < .03), suggesting that low-dose rapamycin (1–10 nM) signifi-
cantly enhances direct CRT-induced cytotoxicity (Figure 2). These
findings are further supported by our in vivo findings that show a
statistically significant prolonging of survival in immunocompromised
Rag-1–deficient mice when rapamycin was administered concurrently
with CRT, as discussed below.
Rapamycin Prolongs Tumor-Bearing Survival and Enhances
Immune-Mediated Tumor Clearance
The therapeutic potential of rapamycin was assessed in vivo using a
previously developed mouse model of HPV+ HNSCC. This model
consists of immortalized C57Bl/6 MOEs retrovirally transduced with
the HPV-16 E6 and E7 oncogenes as well as an activated H-Ras gene
(E6/E7/Ras cells) injected into the subcutaneous flank of syngeneic
mice (as described in greater detail in Materials and Methods sec-
tion above). Daily rapamycin treatment alone in immunocompetent
mice was not sufficient for tumor clearance (Figure 3A), but growth
was inhibited enough to the point that tumor-bearing survival time
was significantly increased (10.6-day median survival increase by
5 mg/kg rapamycin, P < .0004). At the tumor level, immunohisto-
chemical analysis revealed greatly inhibited mTOR signaling through
phosphorylated ribosomal S6 staining with rapamycin treatment (Fig-
ure 3B). In three separate experiments, when mice were subjected
to a 3-week rapamycin regimen concurrent with CRT, rapamycin-
treated mice (5 mg/kg) showed a consistent 20% to 30% increase in
tumor-free survival to vehicle + CRT–treated mice. The combined
overall survival for these three experiments shows a dose-dependent
increase in tumor-free survival, with a 21% overall increase (P ≤ .055)
in the highest rapamycin dose + CRT–treated groups compared to
vehicle + CRT (Figure 3C). In this wild-type, immunocompetent set-
ting, rapamycin actually increased the number of animals that went
on to be tumor-free.
To evaluate the role of the immune system, immunocompromised,
Rag-1–deficient C57Bl/6 mice (which lack mature T and B cells [25])
were subjected to the same treatment regimens. Significant increases in
tumor-bearing survival were seen with daily rapamycin alone (10 days
by 1 mg/kg rapamycin, P < .006; 9.6 days by 5 mg/kg rapamycin, P <
.004), but all mice eventually succumbed to their tumor burden (Fig-
ure 4A), as in the wild-type mice. CRT in these immunocompromised
(Rag) mice greatly increased survival time (29 days with vehicle + CRT
compared to vehicle alone), and rapamycin lengthened this survival
time even further (11 days by 1 mg/kg rapamycin, P < .0003; 22.7 days
by 5 mg/kg rapamycin, P < .00001), but in the absence of an adaptive
immune response, no mice were able to clear their tumors (Figure 4B).
These findings were in support of our past findings that an immune
response is necessary for clearance of this tumor type and suggest that
rapamycin both enhances the effects of CRT (Rag mice), as discussed
above, as well as enhances the immune-mediated clearance of HPV+
tumors (wild-type mice).
In these experiments, rapamycin was very well tolerated by the
animals. Weight loss was the only significantly appreciated side effect
evident in rapamycin + CRT–treated mice (data not shown), with some
weight loss a common side effect of CRT alone. As low-weight animals
rapidly recovered weight after completion of their treatment regimens
(data not shown), rapamycin may be a relatively safe way to enhance
long-term cures of HPV+ HNSCC without significantly increasing the
systemic toxicities of CRT.
Rapamycin Attenuates Tumor Lactate Levels
The enhanced tumor clearance observed in wild-type mice could be
related to several possible mechanisms. Our past work (in preparation),
and that of others [26–29], have shown that tumor lactate produc-
tion inhibits immune responses. Activated mTOR signaling promotes
lactate production as a byproduct of upregulated metabolism (through
GLUT1, pyruvate kinase M2, LDH, and other downstream mecha-
nisms [18,19]), and lactate in the tumor microenvironment has been
Figure 2. Rapamycin enhances the direct CRT-induced cytotoxicity
in clonogenic assays. E6/E7/Ras MOEs allowed to establish for
24 hours were treated with rapamycin at the indicated concentra-
tions for an additional 24 hours. Cells were then dosed with cisplatin
and radiation with rapamycin treatment continued concurrently.
After 1 week, colonies were fixed, stained, and counted. Represen-
tative images of the colonies formed at each rapamycin concen-
tration with equal cisplatin and radiation dosing in all conditions are
shown in A. Average colony number at each concentration is shown
in B, and average colony size is shown in C. Rapamycin was seen
to enhance the direct CRT-induced cytotoxicity to this model
HPV+ HNSCC cell line, with fewer (*P < .03, **P < .01) and smaller
(*P< .03, **P< .03) colonies forming in the presence of rapamycin.
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shown to inhibit immune cell functions [26–28], including those
specific for CD8+ cells [29]. Knowing HPV+ HNSCC clearance is
CD8+ dependent [25], we thus hypothesized that metabolic down-
regulation by rapamycin could plausibly enhance the immune response
necessary for HPV+ tumor clearance. Rapamycin was able to sig-
nificantly diminish lactate production in vitro as determined by color-
imetric lactate assay of culture media of both 4-hour rapamycin-treated
HPV+ human (SCC47: 1 nM, P < .01; 10 nM, P < .05; 100 nM, P <
.02; SCC90: 10 nM, P < .02; 100 nM, P < .02) and mouse (E6/E7/Ras
MOE: 10 nM, P < .02; 100 nM, P < .05) SCCs (Figure 5A). Though
differing levels of lactate were reached in the 4-hour treatment time
among the tested cell lines, these levels directly correlate with the
intrinsic growth rates of the cell lines and thus are indicative of differing
rates of lactate production rather than reflective of absolute achievable
levels such as in the in vivo tumor microenvironment. Moreover, rapa-
mycin significantly decreased the lactate levels in a dose-dependent
Figure 3. Rapamycin inhibits mTOR signaling at the tumor level to prolong survival and enhance CRT-induced tumor clearance in wild-type
mice. (A) Kaplan-Meier survival analysis with log-rank significance test in wild-type male C57Bl/6 mice with E6/E7/Ras MOE tumors of the
right flank receiving daily i.p. rapamycin or vehicle (0 mg/kg, n= 7; 1 mg/kg, n= 6; 5 mg/kg, n= 6; 0 to 1 mg/kg, NS; 1 to 5 mg/kg, NS; 0 to
5 mg/kg, P < .0004). (B) Phospho-S6 immunohistochemical staining of tumor sections harvested at end point showing inhibited mTOR
signaling with rapamycin treatment (1 mg/kg). (C) Survival analysis with log-rank significance test in wild-type male C57Bl/6 mice receiving
daily rapamycin or vehicle for 21 days concurrent with once weekly cisplatin (0.132 mg/mouse) and radiation (8 Gy) for 3 weeks. The com-
binedoverall survival for three separate replicatesof theexperiment is shown (0mg/kg,n=30;1mg/kg,n=28; 5mg/kg,n=25;0 to 1mg/kg,
NS; 1 to 5 mg/kg, NS; 0 to 5 mg/kg, P≤ .055). A rapamycin dose-dependent increase in tumor-free survival concurrent with equal dosing of
CRT was observed, 27% with CRT alone, 39% at 1 mg/kg rapamycin + CRT, and 48% at 5 mg/kg rapamycin + CRT. The highest dose
of rapamycin concurrent with CRT showed a 21% overall increase in tumor-free survival in wild-type mice compared to vehicle.
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manner in all of the cell lines tested irrespective of the absolute lactate
level obtained in 4 hours in vitro. In vivo, when E6/E7/Ras tumors
from daily rapamycin-treated end-point mice (as described in Materials
and Methods section) were sectioned and subjected to quantitative
lactate bioluminescence ex vivo using a lactate-dependent luciferase-
containing buffer system [34] (Figure 5B), tumor lactate levels were
also seen to be significantly decreased compared to vehicle-treated
mice (1 and 5 mg/kg rapamycin, P < .0002). Therefore, rapamycin
is capable of attenuating tumor cell metabolism as indicated by reduced
lactate production.
Lactic Acid Inhibits Cell-Mediated Immunity to
HPV+ HNSCC
To then assess whether or not lactate is capable of attenuating HPV-
related cell-mediated immunity (CMI), splenocytes isolated from
HPV-16 E6/E7-vaccinated mice were co-cultured with irradiated E6/
E7/Ras MOEs in known concentrations of lactic acid in media. Lactic
acid was used, as lactate transport out of a cell is coupled to a proton
gradient (see Discussion section below). Flow cytometry was then used
to identify CFSE-stained epithelial cancer cell populations, and cell-
mediated immune killing was quantified using the mean fluorescent
intensity of the DNA intercalator and dead cell stain, TO-PRO-3,
within the cancer cell populations. The mean fluorescent intensity of
TO-PRO-3 did not significantly change in the presence of lactic acid
alone [0 to 5 to 10 mM lactic acid, not significant (NS)] but was sig-
nificantly increased in the presence of lymphocytes at all lactic acid
concentrations (P < .02), indicating cell-mediated killing of the cancer
cells with negligible acid effect itself. However, increasing concen-
trations of lactic acid significantly decreased (10 mM lactic acid, P <
.005) the mean fluorescent intensity of TO-PRO-3 in the presence of
lymphocytes (Figure 6A). As a possible explanation, a dose-dependent
decrease in total perforin, the pore-forming protein released from
CD8+ cells that allows the apoptosis-initiating granzyme B protease to
enter the target cell, was observed in response to concentrations of
lactic acid at 10 mM and above (Figures 6B and W2). These findings
indicate that elevated lactate levels, as associated with upregulated
metabolism, have the ability to reduce immune-mediated death of E6
and E7–expressing cancer cells.
Discussion
Our recent work [9,25] has shown that successful long-term cures
of HPV+ HNSCC with the current therapies of cisplatin and radia-
tion have two mechanisms that are therapy related: 1) direct cell
toxicity from both cisplatin and radiation and 2) an immune re-
sponse induced during CRT. An ideal innovative drug to further
improve survival in these patients would thus have three aspects:
1) it would further increase tumor-specific direct cell toxicity for CRT,
2) it would further enhance immune-related clearance that is induced
by cisplatin and radiation, and 3) it would not increase systemic toxicity
or morbidity. A drug that targets the viral-mediated changes of metabo-
lism may possess these ideal characteristics for therapy. Thus, inhibiting
virally enhanced mTOR signaling is likely to be a valuable therapeutic
approach in HPV+ HNSCC.
mTOR inhibitors have been tested extensively in humans without
severe adverse increases in systemic toxicity or morbidity. Yet, inhib-
iting mTOR may enhance direct toxicity to dependent HPV+ cancer
cells, as suggested by our data, because the cells then lack antiapoptotic
and key survival signals downstream of mTOR and cap-dependent
translation, which are otherwise known to be induced by CRT [38].
In addition, past work and the data presented here suggest that reduced
lactate production promotes CMI. HNSCCs have not only been
shown to have high mTOR activity [39] but have also been shown
to overexpress downstream metabolic enzymes including LDH [40],
an indicator of poor prognosis. Targeting of mTOR downregulates
these enzymes and impedes growth signaling, attenuating metabolism
and, subsequently, lactate production. Lactate is transported from a
Figure 4. Rapamycinprolongssurvival andenhancesCRT in immuno-
compromised mice but does not lead to any long-term cures.
(A) Kaplan-Meier survival analysis with log-rank significance test in
immunocompromised, Rag-1–deficient male C57Bl/6 mice with E6/
E7/Ras MOE tumors receiving daily rapamycin treatment or vehicle
(for all groups, n = 5; 0 to 1 mg/kg, P < .006; 1 to 5 mg/kg, NS; 0 to
5 mg/kg, P< .004). (B) Survival analysis with log-rank significance test
in Rag-1–deficient, immunocompromised male C57Bl/6 mice receiv-
ing daily rapamycin or vehicle for 21 days concurrent with CRT as de-
scribed above (0 mg/kg, n= 10; 1 mg/kg, n= 9; 5 mg/kg, n= 9; 0 to
1mg/kg, P< .0003; 1 to 5mg/kg, P< .002; 0 to 5mg/kg, P< .00001).
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cell with a proton in the form of lactic acid and has been suggested to
reach concentrations of up to 40 mM in the microenvironment of solid
tumors and 20 mM in cell culture ([29] and references therein). In-
deed, concentrations upward of 10 mM are feasible also on the basis
of our data. These high lactate concentrations can affect the cytotoxic
activity of CD8+ lymphocytes, which is supported by our findings.
This appears to be specific to lactic acid and not a general acid effect,
as demonstrated by Fischer et al. when comparing the inhibition of
cytotoxic T-lymphocytes by lactic to that by hydrochloric acid [29].
This is explained at least in part through abolishment of lactate/proton
co-transport down their concentration gradient into the extracellular
space. Intracellular accumulation of lactate ultimately culminates in a
metabolic blockade, reducing the translation and subsequent availabil-
ity of intracellular perforin, the primer of cell-mediated cytotoxicity,
among other proteins [29]. mTOR inhibition thus plausibly enhances
immune-related tumor clearance, as induced by CRT and seen in our
animal studies.
This is not to say that other players in the tumor microenvironment
do not affect immune and therapeutic responses in other ways but
highlights a likely contributing factor and the importance of under-
standing the role of the tumor microenvironment. In addition to effects
on other immune cell functions [26–29], elevated tumor lactate levels
have been associated with radioresistance [41], enhanced malignant
behavior through up-regulation of vascular endothelial growth factor
and HIF1α, and enhanced cellular motility [42]. Local acidification
associated with lactate also has positive effects on matrix degradation,
and lactate has been shown to induce other factors important for
tumor progression such as CD44, hyaluronic acid, and transforming
growth factor–β [43]. Lactate has also been suggested to play a role
in symbiotic cancer-stromal interactions, whereby a tumor favorable
Figure 5. Rapamycin attenuates tumor cell lactate production. (A) In vitro lactate assay. E6/E7/Ras MOEs or HPV+ SCCs plated to 100%
confluence were incubated for 4 hours in the presence of the indicated doses of rapamycin. The media was then subject to a commercially
available colorimetric lactate assay, the concentration determined through standard curve, and the results plotted as average lactate concen-
tration per dosage group (n=3). Rapamycin significantly decreased lactate production in both HPV+SCC (SCC47: 1 nM, P< .01; 10 nM, P<
.05; 100 nM, P< .02; SCC90: 10 nM, P< .02; 100 nM, P< .02) and E6/E7/RasMOE (10 nM, P< .02; 100 nM, P< .05) cell lines. (B) Quantita-
tive lactate bioluminescence. Lactate levels were visualized in end-point tumor sections of E6/E7/Ras tumors from daily vehicle or rapamycin-
treated C57Bl/6 mice using a lactate-dependent luciferase-containing buffer system as described by Broggini-Tenzer et al. [34]. Intensities
of bioluminescent images of six (n = 6) tumor sections from multiple mice at each dosage group were averaged. A representative image is
shown alongside tabulated mean bioluminescent intensity and P values compared to control per dosage group (1 to 5 mg/kg, NS).
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microenvironment is created, reciprocal metabolites are provided, and
metabolic reprogramming is induced under control of the downstream
target of mTOR, HIF1α [44]. Taken together with its control over
the metabolic enzymes of lactate production, our results suggest that
mTOR represents a strong candidate therapeutic target for immuno-
genic, HPV-related cancers, which exhibit elevated mTOR function
[14,39], and that mTOR inhibition logically accents standard-of-care
CRT for HPV+ HNSCC.
Though HPV− HNSCCs are known to commonly harbor activat-
ing mutations in the mTOR signaling pathway [15,35], our studies
focused on hypotheses of improving tumor clearance through mecha-
nisms of enhanced immune response. The HPV− cell lines tested in
this work did show mTOR and growth inhibition with rapamycin
treatment. Thus, HPV− cancers, or any showing some mTOR depen-
dence, may be susceptible to the enhanced direct cell killing of the
CRT/rapamycin combination suggested by our in vitro and Rag mouse
studies. Yet, the role of the immune system regarding HPV− cancers is
less well understood. It is likely that other non-HPV tumor antigens
are present and aid in clearance in at least a subset of HPV− cancers
because immunosuppressed patients respond worse to treatment.
Inhibition of mTOR has been shown to be promising therapeutically
for HPV−HNSCCs ([39] and references therein), which is preliminar-
ily supported by our in vitro findings, but further work is necessitated
to evaluate mTOR inhibition concurrent to CRT for HPV− HNSCC
in light of the immune system. Fortunately, there are a number of
clinical trials of mTOR inhibitors combined with various treatment
modalities for HNSCC underway [45], which should help to address
this uncertainty of the HPV− cancers, but careful retrospective analysis
will be necessary as the improved treatment response of HPV+
HNSCCs can be confounding as a cancer type now recognized as a
distinct clinical entity.
In addition to the known, and likely contributory, suppressive
effects on cancer cell proliferation and angiogenesis, mTOR inhibition
may also enhance CRT of HPV+ HNSCC beyond impeded survival
signals and disinhibition of immune cell function through some yet
to be fully elucidated combinatorial sensitizing mechanism, such as
enhancement of immunogenic cell death. Signaling through mTOR
normally inhibits autophagy, which can act as an immunogenic form
of cell death. mTOR inhibition has been shown to enhance autophagy
[46], which is also induced by CRT [47,48], thus providing a possible
explanation for the enhancement of both direct CRT-induced cyto-
toxicity and immune-mediated tumor clearance suggested by this work.
Furthermore, inhibitors of mTOR, through stimulation of autophagy,
have been shown to synergize with cisplatin in the killing of oropha-
ryngeal carcinoma [49]. However, the specific cell death mechanism
is important as autophagy can also be cytoprotective [50] and not all
forms of cell death are immunogenic [51]. Future work is necessary
for identification of the predominant cell death mechanism induced
by the rapamycin/CRT combination.
Of interest, our results also suggest that mTOR inhibition by rapa-
mycin with and without the combination of standard-of-care CRTmay
also be of benefit to immunocompromised HPV+ cancer patients, such
as patients with human immunodeficiency virus/acquired immuno-
deficiency syndrome (HIV/AIDS) who have an inherently increased
risk of HPV infection and associated cancers [52,53]. Though our data
suggests that an intact immune system is necessary for tumor clear-
ance, significantly prolonged tumor-bearing survival was observed in
immunocompromised animals receiving rapamycin with and without
CRT. It is therefore possible that rapamycin may prolong survival
and potentially enhance tumor clearance even when immune response
is weakened by HIV or in other immunosuppressive conditions. In
addition to HIV patients, high-risk HPV infection and increased risk
of subsequent carcinogenesis has been associated with many states of
chronic immune suppression, such as after renal transplant (an instance
when rapamycin is commonly prescribed in an immunosuppressant
combination to prevent organ rejection) and with autoimmune diseases
[54,55], making our findings potentially widely applicable.
This work adds to the knowledge of virally related metabolic changes
and may help to translate that knowledge into newer, safer therapies
that can augment the current standard-of-care treatment of HPV+
HNSCC. mTOR is one such therapeutic target that may prove to
be effectively inhibited concurrent with standard-of-care platinum-
based chemotherapy and radiation, enhancing direct cytotoxicity and
inhibiting tumor growth and lactate production to allow for a more
effective immune response to this antigenic tumor type without in-
creasing systemic toxicities. These findings may have broad implica-
tions for many solid cancers showing mTOR dependence and that
are treated with chemoradiation, particularly those expressing viral
antigens, and may impact their clinical management.
Figure 6. Lactic acid inhibits CMI and decreases lymphocyte per-
forin levels specific to our HPV+ HNSCC tumor model. (A) CMI
assay. CFSE-stained E6/E7/Ras cells were irradiated (30 Gy) and
co-cultured for 24 hours with isolated mixed lymphocytes from
the spleens of mice vaccinated with Ad5 E6/E7 [6] at 0, 5, and
10 mM lactic acid in media (RPMI) followed by dead cell staining
(TO-PRO-3) and flow cytometry. CFSE-positive cells were gated
and mean TO-PRO-3 signal averaged (n= 3) for each dosage group.
In all dosage groups, the presence of lymphocytes led to signifi-
cantly increased dead cell staining (P < .02), while lactic acid in
the absence of lymphocytes did not itself induce any cell death
(splenocytes: 0, 5, and 10 mM, NS). A trend of decreasing dead cell
staining with increasing lactic acid concentration was observed.
At 10 mM lactic acid, cell-mediated cytotoxicity was significantly
decreased as indicated by decreased dead cell staining (*P <
.005). (B) Lymphocytes cultured alone in lactic acid for 24 hours
showed a dose-dependent decrease byWestern blot in total perforin,
the primer of CMI. Concentrations of lactic acid at 10 mM and
higher were tested as significant inhibition of CMI was not seen at
less than 10 mM. The blot has been cropped for presentation and
can be seen in full in Figure W2.
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Figure W1. Full-length Western blots with size markers of downstream targets of mTOR corresponding to those shown in Figure 1 of
the main text. Blots for P-S6K, total S6K, and 4EBP1 are shown. β-Actin is shown as a loading control. (A) Primary HTEs are compared to
four tonsillar SCC lines, two HPV− (SCC1 and SCC84) and two HPV+ (SCC47 and SCC90), after 24 hours of treatment with 10 nM
rapamycin or vehicle. (B) A retrovirally transduced and immortalized HPV+ mouse oropharyngeal epithelial (MOE) cell line possessing
the E6 and E7 oncogenes (E6/E7) is compared to an empty vector containing control line (LXSN).
Figure W2. Full-length Western blot with size markers of mouse
perforin corresponding to the blot shown in Figure 6 of the main
text. β-Actin is shown as a loading control. Perforin was blotted
from whole-cell lysates of mixed lymphocytes that were cultured
for 24 hours at 0, 10, and 20 mM lactic acid in media (RPMI),
which were isolated from the spleens of mice vaccinated with
Ad5 E6/E7.
